Minneapolis, MN, United States
Minneapolis, MN, United States

Time filter

Source Type

News Article | May 12, 2017
Site: www.prnewswire.com

Browse 157 market data tables and 76 figures spread through 212 pages and in-depth TOC on "Cell Signaling Market" Early buyers will receive 10% customization on this report. The cell signaling market is expected to reach USD 3.51 Billion by 2022 from USD 2.53 Billion in 2017, at a CAGR of 6.8% from 2017 to 2022. Growth in the cell signaling market is driven by the rising incidence of chronic diseases, availability of funding for cell-based research, technological advancements in cell-based research instruments, and the growth of the life science and biopharmaceutical industries. This report segments the cell signaling market on the basis of product, pathway, signaling type, technology, application, and region. Based on product, the market is segmented into consumables and instruments. The cell signaling consumables segment is estimated to account for the largest share of the cell signaling market in 2017. The increasing number of cell signaling research activities and rising incidence of chronic diseases are some of the major factors contributing to the segments large market share. By pathway, the cell signaling market is segmented into AMP-activated protein kinase (AMPK), Akt, ErbB/HER, Hedgehog (Hh), NF-êB, Janus kinase and signal transducer and activator of transcription (JAK/STAT), Notch, and other signaling pathways. The Akt pathway segment is estimated to account for the largest share of the cell signaling market in 2017. Based on signaling type, the market is segmented into paracrine, endocrine, autocrine, juxtacrine, and other signaling types (intracrine and neuronal signaling). The endocrine segment is estimated to account for the largest share of the cell signaling market in 2017. On the basis of technology, the cell signaling market is segmented into enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), microscopy, flow cytometry, western blotting, mass spectrometry, and other technologies (immunofluorescence and immunoprecipitation). The microscopy segment is estimated to account for the largest share in 2017. Based on application, the market is segmented into research applications (cancer research, immunology research, stem cells research, and other research applications) and medical applications. The research applications segment is estimated to account for the largest share of the cell signaling market in 2017. On the basis of region, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to account for the largest share of the cell signaling market in 2017. Growth in this regional segment is driven by the growth in geriatric population, rising incidence of chronic diseases, and improved life science research infrastructure in the region. The key players in the cell signaling market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Beckman Coulter, Inc. (U.S.) (a subsidiary of Danaher Corporation), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer Inc. (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Abcam plc (U.K.), Miltenyi Biotec (Germany), Full Moon BioSystems, Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Cisbio Bioassays (France), Rockland Immunochemicals Inc. (U.S.), BioVision, Inc. (U.S.), Tonbo Biosciences (U.S.), BPS Bioscience, Inc. (U.S.), StressMarq Biosciences Inc. (U.S.), Abeomics, Inc. (U.S.), Sino Biological, Inc. (U.S.), RayBiotech, Inc. (U.S.), MEDICAL & BIOLOGICAL LABORATORIES CO.,LTD. (Japan), and Santa Cruz Biotechnology, Inc. (U.S.). Cell Analysis Market By Product (Instrument (PCR, HCS, Spectrophotometer, Microscope), & Consumables (Assay, Reagent)), by Process (Cell Proliferation, Single Cell Analysis), & by End User (Hospital, Pharmaceutical, Biotechnology, CRO) - Forecast to 2020 MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


News Article | May 12, 2017
Site: www.prnewswire.co.uk

Browse 157 market data tables and 76 figures spread through 212 pages and in-depth TOC on "Cell Signaling Market" Early buyers will receive 10% customization on this report. The cell signaling market is expected to reach USD 3.51 Billion by 2022 from USD 2.53 Billion in 2017, at a CAGR of 6.8% from 2017 to 2022. Growth in the cell signaling market is driven by the rising incidence of chronic diseases, availability of funding for cell-based research, technological advancements in cell-based research instruments, and the growth of the life science and biopharmaceutical industries. This report segments the cell signaling market on the basis of product, pathway, signaling type, technology, application, and region. Based on product, the market is segmented into consumables and instruments. The cell signaling consumables segment is estimated to account for the largest share of the cell signaling market in 2017. The increasing number of cell signaling research activities and rising incidence of chronic diseases are some of the major factors contributing to the segments large market share. By pathway, the cell signaling market is segmented into AMP-activated protein kinase (AMPK), Akt, ErbB/HER, Hedgehog (Hh), NF-êB, Janus kinase and signal transducer and activator of transcription (JAK/STAT), Notch, and other signaling pathways. The Akt pathway segment is estimated to account for the largest share of the cell signaling market in 2017. Based on signaling type, the market is segmented into paracrine, endocrine, autocrine, juxtacrine, and other signaling types (intracrine and neuronal signaling). The endocrine segment is estimated to account for the largest share of the cell signaling market in 2017. On the basis of technology, the cell signaling market is segmented into enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), microscopy, flow cytometry, western blotting, mass spectrometry, and other technologies (immunofluorescence and immunoprecipitation). The microscopy segment is estimated to account for the largest share in 2017. Based on application, the market is segmented into research applications (cancer research, immunology research, stem cells research, and other research applications) and medical applications. The research applications segment is estimated to account for the largest share of the cell signaling market in 2017. On the basis of region, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to account for the largest share of the cell signaling market in 2017. Growth in this regional segment is driven by the growth in geriatric population, rising incidence of chronic diseases, and improved life science research infrastructure in the region. The key players in the cell signaling market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Beckman Coulter, Inc. (U.S.) (a subsidiary of Danaher Corporation), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer Inc. (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Abcam plc (U.K.), Miltenyi Biotec (Germany), Full Moon BioSystems, Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Cisbio Bioassays (France), Rockland Immunochemicals Inc. (U.S.), BioVision, Inc. (U.S.), Tonbo Biosciences (U.S.), BPS Bioscience, Inc. (U.S.), StressMarq Biosciences Inc. (U.S.), Abeomics, Inc. (U.S.), Sino Biological, Inc. (U.S.), RayBiotech, Inc. (U.S.), MEDICAL & BIOLOGICAL LABORATORIES CO.,LTD. (Japan), and Santa Cruz Biotechnology, Inc. (U.S.). Cell Analysis Market By Product (Instrument (PCR, HCS, Spectrophotometer, Microscope), & Consumables (Assay, Reagent)), by Process (Cell Proliferation, Single Cell Analysis), & by End User (Hospital, Pharmaceutical, Biotechnology, CRO) - Forecast to 2020 MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


— This report studies the global Cell Signaling market, analyzes and researches the Cell Signaling development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Merck KGaA Thermo Fisher Scientific Becton, Dickinson and Company Beckman Coulter Bio-Rad Laboratories Perkinelmer Qiagen Cell Signaling Technology Promega Corporation Bio-Techne Corporation Market segment by Type, Cell Signaling can be split into Endocrine Signaling Paracrine Signaling Autocrine Signaling Juxtacrine Signaling Other Signaling Types Market segment by Application, Cell Signaling can be split into Research Applications Medical Applications Some Points from Table of Content: Chapter One: Industry Overview of Cell Signaling 1.1 Cell Signaling Market Overview 1.1.1 Cell Signaling Product Scope 1.1.2 Market Status and Outlook 1.2 Global Cell Signaling Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Cell Signaling Market by Type 1.3.1 Endocrine Signaling 1.3.2 Paracrine Signaling 1.3.3 Autocrine Signaling 1.3.4 Juxtacrine Signaling 1.3.5 Other Signaling Types 1.4 Cell Signaling Market by End Users/Application 1.4.1 Research Applications 1.4.2 Medical Applications Chapter Two: Global Cell Signaling Competition Analysis by Players 2.1 Cell Signaling Market Size (Value) by Players (2016 and 2017) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future Chapter Three: Company (Top Players) Profiles 3.1 Merck KGaA 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Cell Signaling Revenue (Value) (2012-2017) 3.1.5 Recent Developments 3.2 Thermo Fisher Scientific 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Cell Signaling Revenue (Value) (2012-2017) 3.2.5 Recent Developments 3.3 Becton, Dickinson and Company 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Cell Signaling Revenue (Value) (2012-2017) 3.3.5 Recent Developments 3.4 Beckman Coulter 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Cell Signaling Revenue (Value) (2012-2017) 3.4.5 Recent Developments 3.5 Bio-Rad Laboratories 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Cell Signaling Revenue (Value) (2012-2017) 3.5.5 Recent Developments 3.6 Perkinelmer 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Cell Signaling Revenue (Value) (2012-2017) 3.6.5 Recent Developments 3.7 Qiagen 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Cell Signaling Revenue (Value) (2012-2017) 3.7.5 Recent Developments 3.8 Cell Signaling Technology 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Cell Signaling Revenue (Value) (2012-2017) 3.8.5 Recent Developments 3.9 Promega Corporation 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 Cell Signaling Revenue (Value) (2012-2017) 3.9.5 Recent Developments 3.10 Bio-Techne Corporation 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 Cell Signaling Revenue (Value) (2012-2017) 3.10.5 Recent Developments Make an enquire of this report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/292448 . For more information, please visit http://www.orbisresearch.com/reports/index/global-cell-signaling-market-size-status-and-forecast-2022


With over 27 years' experience, Reza Vahabzadeh has a strong track record in the Consumer sector, having been involved in numerous transactions across the food, beverage, restaurant, and health/personal care industries, for clients including B&G Foods, Henkel, Hostess Brands and Pinnacle Foods. Prior to joining Rothschild, Mr. Vahabzadeh was a Senior Advisor to the Global Consumer Practice at Perella Weinberg Partners in New York, after spending 13 years at Lehman/Barclays as their High Yield Research Analyst covering the Consumer Products sector. He achieved Institutional Investor's #1 ranking in the space for 12 consecutive years. Mr. Vahabzadeh started his career at Bank of America in Los Angeles, and also worked at Transamerica Investment Management, Credit Suisse and Lehman Brothers. He holds a B.S. in Finance and Accounting, Magna Cum Laude from Boston College and an MBA in Finance from UCLA. Siddharth Hariharan joins Rothschild after 13 years at J.P. Morgan, where he was most recently the Executive Director and Head of Emerging Brands. While at J.P. Morgan, Mr. Hariharan developed a niche expertise in the Consumer sector, working on a number of consumer focused debt, equity and M&A transactions. He has advised clients including Fossil, Clorox, Planet Fitness, Nike and Under Armour, among others. Mr. Hariharan received his B.S. degree in Finance from Indiana University. Aashis Mehta comes to Rothschild from Lazard, where he was a member of their Healthcare Group. While at Lazard, Mr. Mehta served as the sole advisor on a number of healthcare M&A, IPO and restructuring transactions, and advised clients including Celerion, Copernicus Group and LabCorp, among others. Before joining Lazard in 2011, he spent seven years in the Healthcare Group at Credit Suisse and three years at Citigroup. Mr. Mehta holds an undergraduate degree from The Wharton School at the University of Pennsylvania. Timothy Hotchandani comes to Rothschild after spending the last seven years at Deutsche Bank, where he was most recently a Managing Director in the firm's Healthcare Group. During his time at Deutsche Bank, Mr. Hotchandani advised on a variety of M&A, debt and equity transactions for clients including Life Technologies, Abbott, Bio-Techne, Danaher, Merck KGaA, Qiagen and Thermo Fisher, among others. Mr. Hotchandani has also worked at Lehman Brothers, Macquarie Capital and Thomas Weisel Partners. He is a member of the Chartered Financial Analyst Institute and holds a B.B.A. in finance and economics, with distinction and Beta Gamma Sigma, from the University of Wisconsin-Madison. "I am excited to expand the depth and breadth of our coverage of the consumer retail landscape with such talented partners as Reza and Sid. Over the past 3 years, our North American franchise has experienced tremendous growth as clients have come to appreciate the differentiated advice and insights that we bring along with the uniquely coordinated reach of our global platform," said Peter "P.J." Moses, Managing Director at Rothschild Global Advisory, who leads the Consumer team in North America. "Jimmy and I look forward to working with all of our new colleagues to continue to grow our business in this market." This news follows the recent announcement that Chris Gaertner has joined Rothschild Global Advisory as the Global Head of Technology, along with Walid Khiari, who joins the firm as a Managing Director on its Technology team. Mr. Gaertner will lead the launch of the firm's new office in the San Francisco Bay Area. About Rothschild & Co Rothschild & Co is a family-controlled and independent business that has been at the centre of the world's financial markets for over 200 years. It is one of the world's largest independent financial advisory groups, employing approximately 3,300 people in over 40 countries around the world. Our integrated global network of trusted professionals provide in-depth market intelligence and effective long-term solutions for our clients in Global Advisory, Private Wealth, Asset Management, and Merchant Banking. Rothschild Global Advisory, a division of the Rothschild & Co Group, designs and executes strategic M&A and financing solutions. It combines the breadth of its advisory offering with a high volume of transactions to achieve a unique understanding and perspective into markets and participants worldwide. Rothschild Global Advisory provides impartial, expert advice to large and mid-sized corporations, private equity, families and entrepreneurs, and governments through an unrivalled network of 900 industry and financing specialists in over 40 countries worldwide. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rothschild--co-adds-four-managing-directors-to-consumer-and-healthcare-teams-in-the-us-300462549.html


News Article | May 2, 2017
Site: www.prnewswire.com

MINNEAPOLIS, May 2, 2017 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2017.  The quarterly dividend will be payable June 2, 2017 to all common shareholders of record on May 19, 2017.  Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $499 million in net sales in fiscal 2016 and has approximately 1,700 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.


— Cell culture protein surface coating is a procedure in which the cell culture surfaces are coated with proteins or extracellular matrix (ECM) components to enhance the adhesion and proliferation of the cells during in vitro isolation and cultivation. Proteins that are used in coating cells are collagen, fibronectin, vitronectin, laminin, and osteopontin, which are either animal derived, plant derived, synthetic, or human derived. Protein surface coating facilitates the growth of various types of cells such as epithelial, leukocytes, muscle cells, neurons, chinese hamster ovary (CHO) cell lines, fibroblasts, and neurons. Publisher's analysts forecast the global cell culture protein surface coating market to grow at a CAGR of 13.20% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global cell culture protein surface coating market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The market is divided into the following segments based on geography: - Americas - APAC - EMEA Publisher's report, Global Cell Culture Protein Surface Coating Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Get Sample of the Report at: http://www.reportsweb.com/inquiry&RW0001713445/sample . Other prominent vendors - Abcam - Agilent Technologies - AM-Pharma - BioLamina - BioMedTech Laboratories - Bio-Techne - BioTime - Caladrius Biosciences - Cedarlane Laboratories - Cell Guidance Systems - CellSystems Biotechnologie Vertrieb - Cellular Dynamics International - Cytoskeleton - Full Moon BioSystems - Greiner Bio-One - GlaxoSmithKline - Histocell - Japan Regenerative Medicine - KANGSTEM BIOTECH - Mesoblast - neuVitro - Orla Protein Technologies - Pall - PerkinElmer - PROGEN Biotechnik - PromoCell - RayBiotech - Sartorius Stedim Biotech - SouthernBiotech - Taiwan Bio Therapeutics - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Trevigen - TWO CELLS - U.S. Stem Cell - Viogene Market driver - Government and research centers to promote research activities. - For a full, detailed list, view our report Market challenge - Ethical concerns over usage of animal-derived protein coating material. - For a full, detailed list, view our report Market trend - Increasing preference for 3D cell cultures over 2D cell cultures. - For a full, detailed list, view our report PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: An overview: Cell culture surfaces PART 06: Market landscape PART 07: Market segmentation by product type PART 08: Geographical segmentation PART 09: Decision framework PART 10: Drivers and challenges PART 11: Market trends PART 12: Vendor landscape PART 13: Key vendor analysis PART 14: Appendix For more information, please visit http://www.reportsweb.com/global-cell-culture-protein-surface-coating-market-2017-2021

Loading Bio-Techne collaborators
Loading Bio-Techne collaborators